Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ver-A-Long long-term verapamil in adults with type 1 diabetes
ISRCTN49549481Phase 2Active, not recruiting
- Sponsor
- Medical University of Graz
- Start
- Nov 2024
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of verapamil in diabetes mellitus type 1 (T1D), sponsored by Medical University of Graz. Primary endpoint: Change in C-peptide response to mixed-meal tolerance test at 24 months. Started Nov 2024; status: active, not recruiting.
02
Drugs
verapamil
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ISRCTN49549481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN49549481.